Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer- a phase II study

Influence of Zonal Dosimetry on Prostate Brachytherapy Outcomes

“…Highdose-rate brachytherapy has the technical advantage of control over post-implant dosimetry, although it is much more invasive than LDR brachytherapy [18]. While there is some evidence to suggest that prostate length is associated with late GU toxicity likely due to greater medial lobe size and correspondingly higher doses to the bladder neck, presumably due to backscatter from the medial lobe to the bladder neck, our data did not demonstrate such a relationship [19][20][21].…”

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

“…Pinkawa et al [40] found increased urinary toxicity with a higher number of needles, and a low number of needles resulted in less homogeneous dose Table 4. Literature review of reporting dose-volume parameters in high-dose-rate prostate brachytherapy.…”

“…Demanes [9] 209 D90, V100, V150 --Edmundson [12] 33 V100, V150 DNR -Hsu [17] 10 V100, V150 COIN, DHI V 80 (r), V 150 (u), V 80 (b) Jacob [20] 20 V100, V150 COIN, DHI V 75 (r), V 125 (u), V 75 (b) Kini [23] 20 V ref , D90 CI, HI -Mahmoudieh [27] 64 V100, V150, V200, D90 CI V150(u), V150(r) Martin [28] 140 V100 CI D r , D u , D mean Martinez [29] 10 D90, D80 -D10(u) Nickers [37] 166 V100, V150 --Nickers [38] 260 V100, V110, V150 --Pinkawa [40] 64 --D 1 (u), D 1 (r) Sathya [44] 138 -CI -Sumida [47] 10 V150, V200 DHI, COIN V150(u) Yoshioka [50] 43 V 100 , V 200 DNR D r , D u Present study 174 V90, V100, V150, V200, D90, D min CI, DNR, DHI, COIN D r , D u , D 2ccm (r), D 0.1ccm (u), D1(u) [48] came to a similar conclusion, when they found increased genitourinal toxicity with a higher number of needles.…”

“…In the paper of Stromberg et al [46], the mean maximum urethra and rectum doses were 111% and 62% of the PD. Pinkawa et al [40] also used the maximum point doses to investigate the relations between the dose to the urethra and rectum, and the side effects. In other studies, dose-volume parameters were used to determine the dose to OARs [29,50].…”

Thermoluminescence dosimetry for in-vivo verification of high dose rate brachytherapy for prostate cancer

“…High dose rate (HDR) brachytherapy is becoming an accepted radiotherapy treatment option for prostate cancer [1][2][3] and is typically employed for delivery of a boost to external beam radiotherapy (EBRT) 4,5 . Similarly to gynecological malignancies, prostate HDRBB dose distributions combine the delivery of higher doses to the prostate while simultaneously restricting the dose to sensitive normal tissues such as bladder, urethra, and rectum compared to delivering the boost using conventional EBRT.…”